In our study cohorts, the OR for breast cancer risk in women with PALB2 P/LP variants was between 8.1 and 9.3 in breast cancer patients compared to non-HBOC cancer patients and non-cancer population, respectively. This evidence concerns the gene PALB2 and breast carcinoma.